Cellectar Biosciences Reports 79.2% Major Response Rate For Iopofosine I 131 In Phase 2 Subset Of Waldenström Macroglobulinemia Patients After BTK Inhibitors

Benzinga Newsdesk www.benzinga.com Positive 91.4%

Neg 0% Neu 0% Pos 91.4%

Comments

No comments yet. Be the first!